Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Healthtrust
Boehringer Ingelheim
Citi
Daiichi Sankyo
Medtronic
Harvard Business School
Moodys
Fuji
Merck

Generated: January 24, 2018

DrugPatentWatch Database Preview

NIASPAN TITRATION STARTER PACK Drug Profile

« Back to Dashboard

When do Niaspan Titration Starter Pack patents expire, and when can generic versions of Niaspan Titration Starter Pack launch?

Niaspan Titration Starter Pack is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-four patent family members in ten countries.

The generic ingredient in NIASPAN TITRATION STARTER PACK is niacin. There are fourteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the niacin profile page.
Summary for NIASPAN TITRATION STARTER PACK
Drug patent expirations by year for NIASPAN TITRATION STARTER PACK
Pharmacology for NIASPAN TITRATION STARTER PACK
Ingredient-typeNicotinic Acids
Drug ClassNicotinic Acid
Medical Subject Heading (MeSH) Categories for NIASPAN TITRATION STARTER PACK

US Patents and Regulatory Information for NIASPAN TITRATION STARTER PACK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NIASPAN TITRATION STARTER PACK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for NIASPAN TITRATION STARTER PACK

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,129,930 Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night ➤ Subscribe
7,998,506 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor ➤ Subscribe
6,818,229 Intermediate release nicotinic acid compositions for treating hyperlipidemia ➤ Subscribe
7,011,848 Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor ➤ Subscribe
6,406,715 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles ➤ Subscribe
6,676,967 Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia ➤ Subscribe
6,746,691 Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for NIASPAN TITRATION STARTER PACK

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Cipla
Merck
Express Scripts
Boehringer Ingelheim
Cerilliant
Chubb
US Department of Justice
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot